- GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted Therapy
-
Huh YE, Usnich T, Scherzer CR, Klein C, Chung SJ
- KMID: 2545923
- J Mov Disord.
- 2023 Sep;16(3):261-278.
- doi: 10.14802/jmd.23023
Glucosylceramidase beta 1 (GBA1) variants have attracted enormous attention as the most promising and important genetic candidates for precision medicine in Parkinson’s disease (PD). A substantial correlation between GBA1 genotypes... -
- CITED
-
- Close
- SHARE
-
- Close
